title: Attenuation of morphine withdrawal signs by a GABAB receptor agonist in the locus coeruleus of rats.
abstract: In the present study, the effects of intra-locus coeruleus (LC) injection of GABA(B) receptor-interacting agents on naloxone-induced withdrawal signs of morphine-dependent rats were examined. The GABA(B) receptor agonist and antagonists were injected 5 min prior to naloxone injection. Baclofen, a GABA(B) receptor agonist, decreased the TWS in a dose-dependent manner but CGP35348, a GABA(B) receptor antagonist, alone had no effect. On the other hand, baclofen effects were reversed by CGP35348. It may be concluded that activation of GABA(B) receptor mechanisms in the LC reduces precipitated withdrawal symptoms from chronic morphine treatment.
authors.affiliation: Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Esmail
authors.initials: E
authors.lastname: Riahi
authors.forename: Iraj
authors.initials: I
authors.lastname: Mirzaii-Dizgah
authors.forename: Seyed Morteza
authors.initials: SM
authors.lastname: Karimian
authors.forename: H R
authors.initials: HR
authors.lastname: Sadeghipour
authors.forename: Hamid Reza Sadeghipour
authors.initials: HR
authors.lastname: Roodsari
authors.forename: Ahmad Reza
authors.initials: AR
authors.lastname: Dehpour
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001418:Baclofen / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D018755:GABA Agonists / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D018756:GABA Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D007279:Injections, Subcutaneous; D008125:Locus Coeruleus / Q000187:drug effects* / Q000503:physiopathology; D008297:Male; D009020:Morphine / Q000008:administration & dosage / Q000633:toxicity*; D009021:Morphine Dependence / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology; D009043:Motor Activity / Q000187:drug effects* / Q000502:physiology; D009270:Naloxone / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D009294:Narcotics / Q000008:administration & dosage / Q000633:toxicity; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology
chemical_list: D018755:GABA Agonists; D018756:GABA Antagonists; D009292:Narcotic Antagonists; D009294:Narcotics; D009943:Organophosphorus Compounds; D009270:Naloxone; D009020:Morphine; C066430:CGP 35348; D001418:Baclofen